Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts

Youssef M. Mousa1, Ihab M. Abdallah1, Misako Hwang2, Douglas R. Martin2,3,4 & Amal Kaddoumi1,4*

A major characteristic of Alzheimer’s disease (AD) is the accumulation of misfolded amyloid-β (Aβ) peptide. Several studies linked AD with type 2 diabetes due to similarities between Aβ and human amylin. This study investigates the effect of amylin and pramlintide on Aβ pathogenesis and the predisposing molecular mechanism(s) behind the observed effects in TgSwDI mouse, a cerebral amyloid angiopathy (CAA) and AD model. Our findings showed that thirty days of intraperitoneal injection with amylin or pramlintide increased Aβ burden in mice brains. Mechanistic studies revealed both peptides altered the amyloidogenic pathway and increased Aβ production by modulating amyloid precursor protein (APP) and γ-secretase levels in lipid rafts. In addition, both peptides increased levels of B4GALNT1 enzyme and GM1 ganglioside, and only pramlintide increased the level of GM2 ganglioside. Increased levels of GM1 and GM2 gangliosides play an important role in regulating amyloidogenic pathway proteins in lipid rafts. Increased brain Aβ burden by amylin and pramlintide was associated with synaptic loss, apoptosis, and microglia activation. In conclusion, our findings showed amylin or pramlintide increase Aβ levels and related pathology in TgSwDI mice brains, and suggest that increased amylin levels or the therapeutic use of pramlintide could increase the risk of AD.
shown that GM1 is involved in the pathogenesis of AD by increasing the production of Aβ through modulating the activity of γ-secretase and APP localization in lipid rafts26,17.

Type 2 diabetes (T2D) has been identified as a risk factor for AD54, and both diseases are pathologically characterized by the presence of misfolded protein aggregates, which result in the formation of Aβ deposits in AD and amylin deposits in T2D19. Amylin (also known as islet amyloid polypeptide) is a 37-amino acid peptide that is co-secreted with insulin from the pancreatic-β cells in response to food intake and works as a satiating hormone60. The misfolded amylin was first isolated from amyloid-rich pancreatic extracts from T2D patients21 in the form of elongated fibrils with many stranded β sheets22. In addition to the formation of amylin deposits in the pancreas, these deposits are found in the brains of AD patients with T2D23. Amylin crosses the BBB and it is suggested to have a role in neural regeneration and glucose metabolism54. Amylin and Aβ have several common features such as having similar β-sheet structures35, binding to the same amylin receptor20, and being degraded by insulin degrading enzyme (IDE)37.

Several studies have shown that amylin is involved in the pathogenesis of AD by inducing neuroinflammation and apoptosis24, but little is known about the mechanism by which amylin exacerbates AD pathology. On the other hand, multiple studies have shown that amylin ameliorated AD pathology by decreasing neuroinflammation and increasing Aβ clearance from brain to blood24–32. In this study, we investigated the effect of amylin and its analog, pramlintide, on Aβ pathology, and identified a novel aspect of amylin and pramlintide in increasing the amyloidogenic processing of APP in TgSwDI mouse, a model for cerebral amyloid angiopathy (CAA) and AD, where both peptides increased γ-secretase complex level and APP localization in lipid rafts. Furthermore, pramlintide significantly increased GM1 ganglioside in lipid rafts and GM2 in total brain homogenate, whereas both peptides increased the ganglioside producing enzyme β-1,4 N-acetylgalactosaminyl transferase 1 (B4GALNT1). Our findings suggest that amylin and pramlintide increased Aβ brain accumulation through modulating APP processing in lipid rafts, and thus could increase the risk of CAA and AD.

Results
Amylin and pramlintide did not alter memory performance compared to vehicle treated mice. Morris water maze (MWM) behavioral test was performed to assess the effect of amylin and pramlintide on learning and memory functions. The following parameters were analyzed, the time a mouse takes to find the platform (latency, s), swimming speed (cm/s), swimming distance (cm) and number of entries in target quadrant. As shown in Fig. S1 (Supplementary Material), amylin and pramlintide have no significant changes in the evaluated parameters when compared to vehicle treated mice (control), suggesting amylin and pramlintide did not alter memory function.

Amylin or pramlintide increased Aβ burden in TgSwDI mice brains. Aβ levels from brain total homogenate were analyzed by ELISA and the results demonstrated that only amylin increased the level of soluble Aβ40 compared to control (p < 0.05), while both amylin and pramlintide significantly increased soluble Aβ40 compared to control group (p < 0.001 and p < 0.05, respectively) (Fig. 1A). Moreover, neither amylin nor pramlintide treatment showed significant changes in the level of insoluble Aβ40, but both showed significant increase in insoluble Aβ42 compared to control (p < 0.01; Fig. 1B). Furthermore, amylin significantly increased oligomeric Aβ42 compared to control and pramlintide (p < 0.01 and p < 0.05, respectively); however, neither treatment altered oligomeric Aβ42 (Fig. 1C). Total Aβ40 and Aβ42 from total protein fraction were also measured following direct extraction with 70% formic acid; as shown in Fig. 1D, amylin significantly increased total levels of Aβ40 only (p < 0.001), while pramlintide increased both Aβ40 (p < 0.05) and Aβ42 (p < 0.001) when compared to control group.

Immunohistochemical analysis of the three groups was performed to show Aβ burden in cortex and hippocampus regions. The captured images showed a significant increase in total Aβ (detected by 6E10) in the brains of both amylin and pramlintide treated mice compared to control when measured in the hippocampus (p < 0.05), and cortex (p < 0.001; Fig. 1E–G). Moreover, the deposition of Aβ plaques (detected by Thio-S) was significantly higher in the brains of mice treated by amylin or pramlintide than the control group in the hippocampus (p < 0.05 and p < 0.01, respectively) and cortex (p < 0.05 and p < 0.01, respectively) (Fig. 1E–G).

Amylin and pramlintide have no clear effect on APP processing pathway when measured in brain homogenate. Findings from Western blot of mouse brain homogenates demonstrated insignificant changes in the level of full-length APP (FAPP) and BACE1 between control and treated mice (Fig. 2a). The cleavage of APP by BACE1 produces sAPP-β and the results demonstrated that only pramlintide significantly increased sAPP-β compared to control (p < 0.05), whereas both amylin and pramlintide significantly decreased the level of sAPP-α in the total brain homogenate compared to control (both, p < 0.01; Fig. 2b). To further understand the effect of amylin and pramlintide on APP processing and to explain the increased Aβ burden in brain homogenates, the four γ-secretase complex subunits, presenilin-1 (PSEN1), presenilin-2 (PSEN2), nicastrin, and PEN2 were measured. Results from the total brain homogenate showed no significant changes in PSEN1, PSEN2, and nicastrin between the control and treated mice (Fig. 2c). On the other hand, only pramlintide demonstrated a significant increase in PEN2 subunit when compared to control and amylin (p < 0.001 and p < 0.05, respectively) (Fig. 2c). Next, to explain whether increased brain Aβ is mediated by γ-secretase, we evaluated levels of β-CTF (or C99) in brain homogenates by Western blotting, and our findings showed both amylin and pramlintide significantly increased β-CTF levels compared to control (p < 0.001 and p < 0.05, respectively) (Fig. 2d). Overall, the results from the total brain homogenate did not provide clear explanation for the increased Aβ burden in the brains of mice treated with amylin and pramlintide.
Amylin and pramlintide modulated APP processing in lipid rafts. Mounting evidence indicates that the amyloidogenic processing of APP occurs in lipid rafts. The DRMs were prepared and fractions enriched in lipid rafts were identified by immunoblotting of lipid raft marker with antibody against flotillin-1. Findings from optimization and characterization of lipid rafts isolation from brain homogenates demonstrated the highest flotillin-1 localization in fraction 2 (the interface between 5 and 35% sucrose in the gradient) (Supplementary Material, Fig. S2), suggesting lipid rafts are enriched in fraction 2, which was used for subsequent analysis for the effect of treatments on protein levels in lipid rafts. In addition, as part of the characterization, proteins involved in the amyloidogenic pathway of APP processing were immunoblotted from each fraction and findings demonstrated the localization of these proteins in fraction 2 (Supplementary Material, Fig. S3), except α-secretase and β-CTF (Supplementary Material, Fig. S4). Based on the results, only pramlintide increased APP in lipid rafts significantly when compared to vehicle treated groups (p < 0.05) (Fig. 3a). Consistent with total brain homogenate results, BACE1 level in the lipid raft was not altered by amylin or pramlintide (Fig. 3a). However, pramlintide and amylin treated mice showed a significant increase in lipid raft levels of PSEN1, PSEN2, nicastrin and PEN2 subunits compared to control (p < 0.05; Fig. 3b). PSEN1, PSEN2 and nicastrin results differed from total brain homogenate.
Amylin and pramlintide modulated GM1, GM2 and B4GALNT1 in total homogenate and/or lipid rafts. Previous reports observed a role of GM1 gangliosides in modulating APP trafficking and processing\(^1\), and in increasing \(\gamma\)-secretase levels in lipid rafts\(^2\). Thus, in this study we evaluated amylin and pramlintide effects on gangliosides synthesis pathway including GM1, GM2, and the enzymes GCS, responsible for the
The biotransformation of ceramide into glucosylceramide, B4GALNT1 that converts GM3 to GM2, and B3GALT4 that converts GM2 to GM1 by addition of galactose. Our results demonstrated amylin and pramlintide have no effect on GCS or B3GALT4 levels in total homogenate (Fig. 4a). However, compared to control, both amylin and pramlintide significantly increased B4GALNT1 levels in total brain homogenate (p < 0.05 and p < 0.001, respectively; Fig. 4a) but not in lipid rafts. GM2 was measured in total brain homogenate and lipid rafts using ELISA. Results showed that pramlintide, but not amylin, increased GM2 by 68% in total homogenate (p < 0.05; Fig. 4c). In contrast, neither amylin nor pramlintide altered GM2 levels in lipid rafts compared to control (Fig. 4c). GM1 levels in total brain homogenate and lipid rafts were also determined; findings from Western blot demonstrated amylin significantly increased GM1 in total brain homogenate (p < 0.05; Fig. 4a), while pramlintide significantly increased GM1 levels in lipid rafts (p < 0.001; Fig. 4b). In addition to the synthetic pathway for GM2 and GM1 gangliosides, their lysosomal degradative pathway was evaluated by measuring the activity of specific lysosomal enzymes responsible for their hydrolysis. Amylin and pramlintide did not alter the lysosomal enzyme activities as shown in Table 1.

**Amylin and pramlintide increased Aβ-related pathology.** Both amylin and pramlintide bind to amylin receptor, which is a heterodimer of calcitonin receptor and receptor activity modifying protein 3 (CTR-RAMP3). To evaluate the effect of daily treatment of either peptide for 30 days on amylin receptor, RAMP3 was analyzed by Western blot in brain homogenate lysate and lipid rafts. While RAMP3 expression could not be detected in lipid rafts, neither peptide altered RAMP3 levels detected as monomer, homodimer or heterodimer when compared to control group (Supplementary Material, Fig. S5).
Figure 4. Effect of amylin and pramlintide effect on ganglioside production. (a) Representative Western blot and densitometry analysis of ganglioside demonstrated amylin and pramlintide did not alter the expression of GCS and B3GALT4; however, both amylin and pramlintide significantly increased the level of B4GALNT1 in total brain homogenate. Furthermore, amylin increased the level of GM1 compared to control group when measured from total brain homogenate. The blotted proteins were normalized to the level of GAPDH. (b) Representative Western blot and densitometry analysis of B4GALNT1 and GM1 in lipid rafts. Only pramlintide increased the level of GM1 in lipids rafts, while neither peptide altered the level of B4GALNT1 in lipid rafts. B4GALNT1 and GM1 were normalized to flotillin-1. The densitometry analysis is from n = 6 mice in each group, and western blot results are representative results from two different mice from each group. (c) Only pramlintide increased GM2 levels when measured from total brain homogenate; however, neither peptide altered GM2 levels in lipid rafts as determined by ELISA for n = 4 mice per group. Proteins were ran on different gels due to their close molecular weights size. Data were normalized to the total protein content from brain homogenate. Data is presented as mean ± SEM and the statistical significance for all result was assessed by student t-test, with *p < 0.05, **p < 0.01, ***p < 0.001 compared to control group.

Table 1. Lysosomal enzyme specific activity in mice brain tissues. Specific activity is expressed as mean ± SEM for the nmol of 4-methylumbelliferone/mg protein per h at 37 °C. Average values were calculated from n = 4 mice from each treatment group. [HexA: A isozyme (αβ) of hexosaminidase; Hex Total: total hexosaminidase activity; β-gal: lysosomal β-galactosidase; α-Man: α-mannosidase].

| Treatment     | HexA  | Hex Total | β-gal   | α-Man  |
|---------------|-------|-----------|---------|--------|
| Control       | 173.7 ± 7.3 | 1601 ± 79.4 | 71.18 ± 6.3 | 1.975 ± 0.307 |
| Amylin        | 1.98 ± 0.31  | 1747 ± 44.8 | 76.83 ± 3.6 | 1.867 ± 0.240 |
| Pramlintide   | 183.5 ± 6.9  | 1821 ± 72.7 | 72.90 ± 4.2 | 2.750 ± 0.050  |
The effect of amylin and pramlintide on pre-synaptic markers SNAP-25 and synapsin-1 and post-synaptic marker, PSD-95, were also evaluated in mice brain homogenate by Western blotting. Both amylin and pramlintide significantly reduced PSD-95 expression ($p < 0.01$ and $p < 0.001$, respectively), without altering SNAP-25 or synapsin-1 levels (Fig. 5a). When tested in lipid rafts, neither peptide altered the levels of PSD-95 nor SNAP-25 compared to control group (Fig. 5b). LRPI was also determined in lipid rafts where both treatments reduced its level significantly ($p < 0.05$, Fig. 5b). The effect of treatments on the apoptotic marker cleaved caspase-3 was also evaluated in brain homogenate, and the results showed amylin and pramlintide significantly increased cleaved caspase-3 levels in mice brains ($p < 0.01$), without altering total caspase 3 (Fig. 5c). Moreover, neither peptide altered the matrix metalloproteinase MMP9 level when compared to control group (Fig. 5c).

$\alpha$-amyloid is cleaved by degrading enzymes such as IDE$^{35}$, whose level is altered in T2D and AD$^{36}$. In this study, treatment with amylin or pramlintide had no significant effect on IDE level compared to control measured from total brain homogenate (Fig. 6A). Neuroinflammation is another hallmark of AD, and increased brain $\alpha$-amyloid levels is associated with microglia activation and astroglisis that produce an inflammatory cascade leading to neuronal toxicity and neurodegeneration$^{37}$. Treatment effects on glial activation markers were evaluated by immunostaining and Western blotting. Pramlintide significantly increased Iba1, a microglia marker when compared to control and amylin ($p < 0.05$ and $p < 0.01$, respectively) (Fig. 6A). However, neither peptide modulated astroglisis as determined by Western bolt and immunostaining of astrocytes marker, glial fibrillary acidic protein (GFAP) in terms of intensity or morphology (Fig. 6A,B).

**Discussion**

Amylin is a gut–brain axis hormone which crosses the BBB$^{38}$ and exert its effect on the CNS$^{39}$. Pramlintide is amylin's clinically available analog, which was developed by substituting prolines at positions 25, 28, and 29 of human amylin to prevent amylin oligomerization or aggregation$^{40}$. Amylin shares similar secondary structure with $\alpha$-amyloid, thus $\alpha$-amyloid binds amylin receptor as well$^{41}$. However, the intracellular signaling is different between the two ligands amylin and $\alpha$-amyloid$^{42}$. Using different AD animal models, multiple studies have shown that amylin ameliorates AD pathology by decreasing neuroinflammation and increasing $\alpha$-amyloid clearance from brain to blood$^{30–32,41}$. On the other hand, a number of studies has shown that amylin is involved in the pathogenesis of AD by inducing neuroinflammation and apoptosis$^{25,28,42–46}$. Findings from our study agree with the latter studies where amylin and pramlintide increased $\alpha$-amyloid production and exacerbated $\alpha$-amyloid-related pathology in TgSwDI mice brains, however, without worsening memory as assessed by MWM. TgSwDI mouse model expresses human APP harboring the Swedish, Dutch and Iowa mutations and it is characterized by early (2 to 3 months of age) and aggressive $\alpha$-amyloid accumulation on the wall of blood vessels and increased $\alpha$-amyloid production$^{47}$.

Our data suggest a previously undisclosed link between APP processing and amylin or pramlintide$^{28,30–32}$. The increased level of amyloidogenic pathway proteins in lipid rafts, and to a lower extent in total brain homogenate, caused by amylin and pramlintide signifies the importance of evaluating APP processing at the plasma membrane level. Amylin and pramlintide increased the expression of $\gamma$-secretase 4-subunits in lipid rafts, an effect that was not fully observed in total homogenate. The increased level of $\gamma$-secretase complex subunits in lipid rafts might be responsible for the increased $\alpha$-amyloid burden as confirmed by our ELISA and immunohistochemistry results, which are consistent with other studies demonstrating APP processing in lipid rafts$^{45,47}$. On the other hand, neither peptide altered BACE1 expression in brain homogenates and lipid rafts, suggesting the observed increase in sAPP-$\alpha$ production by pramlintide is due to increased APP trafficking to the lipid raft.

To explain the observed effect of amylin and pramlintide on the amyloidogenic processing of APP in lipid rafts, the effect of both peptides on the synthesis of GM1 and GM2 gangliosides was evaluated. Several studies have reported that GM1 and GM2 are involved in AD pathology$^{43,33,39}$. Using different AD animal models, multiple studies have shown that $\alpha$-amyloid levels where increased levels of B4GALNT1 by amylin and pramlintide was associated with increased levels of $\alpha$-amyloid$^{44}$. Furthermore, analysis of other gangliosides demonstrated only pramlintide increased GM2 levels when measured in total brain homogenate without altering its effect in lipid rafts. To explain the increased levels of GM1 caused by amylin, B3GALT4, the enzyme responsible for GM1 synthesis from GM2, was analyzed and results showed neither amylin nor pramlintide altered this enzyme. Next, and as the increased level of GM1 and GM2 could also be explained by alteration in their lysosomal degradation, the activity of $\beta$-gal which cleaves GM1 to GM2, and HexA which cleaves GM2 to GM3, were evaluated. However, data showed no significant alteration in lysosomal...
enzyme activities. Collectively, while further investigation is necessary, our findings suggest increased GM1 levels could be explained indirectly by increased B4GALNT1, which increased GM2 ganglioside, the precursor of GM1. However, GM2 increase was only observed with pramlintide.

Figure 5. Effect of amylin and pramlintide on Aβ-related pathology. (a) Representative Western blot and densitometry analysis of synaptic markers in mice brain homogenates showed amylin and pramlintide significantly reduced the level of PSD-95, without affecting SNAP-25 and synapsin-1 in total brain homogenate. Data were normalized to β-actin. (b) Representative Western blot and densitometry analysis of synaptic markers and LRP1 in lipid rafts. Amylin and pramlintide had no effect on PSD-95 and SNAP-25 levels in lipid rafts; however, both peptides decreased the level of LRP1. All proteins from lipid rafts were normalized to flotillin-1. (c) A representative Western blot and densitometry analysis demonstrated that amylin and pramlintide significantly increased cleaved caspase-3 (Cle.Cas-3) compared to amylin and control group without affecting the levels of total caspase-3 (Cas-3) and MMP9. MMP9 was ran on different gel due to molecular weight similarity. All proteins were normalized to their corresponding housekeeping proteins. The densitometry analysis is from n = 6 mice in each group. The western blot results are representative results from two different mice from each group. Data is presented as mean ± SEM and the statistical significance for all result was assessed by student test, with *p < 0.05, **p < 0.01, and ***p < 0.001.
Amylin and pramlintide significantly reduced sAPP-α, a finding that is consistent with previously reported studies demonstrated that SH-SYSY-APP695 treatment with GM1 significantly decreased sAPP-α17. Stiffening of the membrane due to a high level of GM1 may decrease sAPP-α by limiting lateral movement and required contact between α-secretase enzyme and substrate17. To confirm the effect of amylin and pramlintide on α-secretase, the enzyme level was determined by Western blot and results showed that neither peptide altered α-secretase level in brain homogenate; on the other hand, we were not able to detect the enzyme in fraction 2 in lipid rafts (Supplementary Material, Fig. S4). The interaction with GM1 has been reported as an important factor in mediating aggregation and toxicity of Aβ and amylin50,51. In addition, amylin interaction with plasma membrane is thought to be the main factor determining the death of pancreatic β-cells in T2D52, where several in vitro studies reported seeding and aggregation of Aβ and amylin on synthetic membrane are enhanced by GM153,54. Increased accumulation of Aβ due to its increased production by amylin and pramlintide could lead to synaptic loss and microglial activation as demonstrated by increased Iba-1, increased apoptotic marker cleaved caspase-3 and reduced post-synaptic marker PSD-95. Increased brain Aβ is expected to activate glial cells and produce inflammatory cascade53. This effect contradicts previously reported neuroprotective effect of amylin against neuroinflammation where amylin reduced Iba1, CD68, and pro-inflammatory cytokines50,51. The reduction in total PSD-95 expression following amylin and pramlintide treatments was associated with reduced LRP1 in lipid rafts fraction, but not in total homogenate. In neuronal cells, LRP1 partitions between both lipid rafts and non-raft membrane fractions55, and it’s signaling activation leads to neurite outgrowth and cell growth56. LRP1 interacts with the active pool of PSD-95 and reduction in total PSD-95 is expected to reduce total LRP1 in neuronal cells57. It has also been reported that localization of LRP1 to lipid rafts reflects the activity of PSD-95, which
is known to cluster other membrane proteins in rafts through its scaffolding activity. Therefore, the reduction in total PSD-95 level due to amylin and pramlintide could explain the reduction in LRP1 in lipid rafts. On the other hand, available studies, unlike our findings, reported pramlintide treatment for 5 weeks increased expression of the presynaptic marker synapsin 1. In this study, the authors used SAMP8 mice at the age of 6 months, and this mouse model exhibits age-related dementia. However, whether similar effect will be observed with pramlintide under pathological insult requires further investigation.

Increased parenchymal Aβ levels and related pathology in the brains of mice treated with amylin and pramlintide for 30 days, however, was not translated to impairment in memory function when compared to vehicle treated mice as determined by MWM behavioral studies. While additional studies are necessary to explain this observation, we speculate that a further decline in memory performance could be observed with the chronic treatment for longer time (i.e. more than 30 days) associated with exacerbated pathology consequent to increased Aβ production in TgSwDI mice brains. Furthermore, while studies with pramlintide are limited in the literature, available studies with amylin show contradicting effects against Aβ-related pathology as well as memory function in AD mouse models. An explanation(s) for this discrepancy is not clear, however, the mouse model used in our study is different from others. In this study we used the CAA/AD model TgSwDI, which is characterized by Aβ deposition not only in the parenchyma but also on brain microvessels. Though we selected a dose and route of administration shown to be protective, the opposite effect was observed. In a review by Qiu et al., the authors explained the discrepancy observed with amylin could be aggregation dependent. For example, treatment of rat cortical neurons with human amylin at 50μM concentration caused neurotoxicity due to amylin aggregation, whereas at the same concentration, rat amylin did not show aggregation or neurotoxicity. Also, at lower concentrations (2.5 nM – 2.5μM), human amylin was able to antagonize aggregated Aβ-induced neurotoxicity. In addition, low vs. high concentrations of amylin could activate different receptors based on the degree of amylin aggregation. In this scenario, the neuroprotective effect of non-aggregated amylin is based on binding a different receptor than that bound by aggregated amylin. Thus, to better understand and clarify amylin and pramlintide effects against AD, dose despondent studies are necessary. Furthermore, additional experiments that would be important to perform include studies in wild type mice as well as in female TgSwDI mice to understand treatments effect in the absence of pathology and whether this effect is sex dependent.

In conclusion, findings from our study suggest that amylin and pramlintide have the potential to increase Aβ-related pathology through modulating γ-secretase activity and APP processing in lipid rafts, and by increasing GM1 ganglioside levels.

Figure 7. Correlation analysis between fold change in B4GALNT1 and Aβ levels revealed positive correlation between B4GALNT1 and soluble Aβ40 (A) and soluble Aβ42 (B), and B4GALNT1 and total Aβ42 (D). The correlation between B4GALNT1 and total Aβ40 (C), on the other hand, was small as demonstrated by low coefficient of determination (R²). For A and B, n = 6 mice/treatment group were used; and for C and D, n = 4 mice/treatment group were used.
Methods
Reagents and antibodies. Synthetic human amylin was purchased from Anaspec (Cat# AS-60254-1), and Pramlintide was purchased from Biotang Inc. (Cat# BF-HOR-300). Brij® 98 was purchased from Thermo Fisher Scientific, thiolavin-S was from Sigma Aldrich and NP-40 lysis buffer was purchased from Alfa Aesar. All other chemicals were purchased from VWR. The following primary antibodies were used to probe the membranes in immunoblotting: anti-human sAPP-β and anti-human sAPP-α (ImmuNo-Biological Laboratories Co., Ltd); anti-APP A4 antibody clone 22C11 and anti-APP-C99 antibody clone M (Millipore); BACE1, LRP1, glucosylceramide synthase (GCS), B4GALNT1, and Iba1 antibodies (abcam); presenilin 1, presenilin 2, nicastrin, PEN2, caspase-3 and synapsin-1 antibodies (Cell Signaling); SNAP-25, zona-occludin 1 (ZO1), occludin, GAPDH, matrix metalloproteinase 9 (MMP9), B3GALT4, Cholera Toxin Subunit B (Recombinant)-HRP, and flotillin 1 antibodies (Invitrogen); IDE, RAMP3, ADAM10 (B-3) for α-secretase and β-tubulin antibodies (Santa Cruz Biotechnology); and PSD-65 antibody (GeneTex). The secondary antibodies used in immunoblotting are goat anti-rabbit IgG (H+L)-HRP and goat anti-mouse IgG (H+L)-HRP (Invitrogen) and goat IgG HRP-conjugated (R&D systems). The following antibodies were used in the immunohistochemistry experiments: rabbit polyclonal collagen IV antibody (Millipore), donkey polyclonal Alexa Fluor 647 antibody to rabbit IgG (abcam), Alexa Fluor-488 conjugated anti-Aβ3 antibody (6E10) (Biolegend), and rabbit GFP antibody (Santa Cruz Biotechnology).

Animal treatment. All animal experiments and procedures were approved by the Institutional Animal Care and Use Committee of the University of Louisiana at Monroe and according to the National Institutes of Health guidelines, as in Principles of Laboratory Animal Care (NIH publication No. 86-23, revised 1996). Males TgSwDI transgenic mice (Jackson Laboratories) at age of 4 months were housed in plastic cages under standard conditions, 12-h light/dark cycle, 22 °C, 35% relative humidity, and ad libitum access to water and food. Mice were treated with i.p. injections of human amylin (200 µg/kg/day; n = 8), pramlintide (200 µg/kg/day; n = 8), or PBS as vehicle (n = 8) for 30 days. At the end of treatment period, mice were deeply anesthetized with ketamine (100 mg/kg) and xylazine (12.5 mg/kg) cocktail i.p., then decapitated for brains collection. Effect of peptides on blood glucose levels was assessed on final day of treatment without significant difference and the readings were 150.7 ± 1, 151.3 ± 0.9 and 151.5 ± 1.5 mg/dl for vehicle, amylin and pramlintide treated mice, respectively (p > 0.05).

Behavioral testing. The Morris water maze (MWM) test was performed for TgSwDI mice to assess learning and memory performance at the end of the treatment using protocols similar to those described previously. All mice underwent training 3 times a day for 4 consecutive days. The platform was kept at the same quadrant during the entire course of the experiment. Mice were required to find the hidden platform utilizing the distal spatial cues available in the room. Conditions were maintained the same during all the experiments. An overhead camera connected to a customized tracking system (SMART 3.0 Platform, Panlab Harvard apparatus (Holliston, MA)) was used to record the movements of the mice. The results including swimming speed, latency to target, swimming distance, and number of entries in target quadrant were collected and used for analysis.

Analysis of Aβ3 burden in mice brains. Brain weights were measured and homogenized in two volumes of DPBS (137 mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl, 0.9 mM CaCl2, 5 mM D-glucose, 0.9 mM MgCl2, 1.46 mM KH2PO4, 1 mM Na-pyruvate) to prepare brain homogenate. Homogenate samples were lysed (1:1.5) with NP-40 lysis buffer containing protease arrest/lyse agent for ice for 45 min. From this homogenate, 100 µl were centrifuged at 20,817 x g for 15 min at 4 °C to collect supernatant/lysate that contain soluble Aβ3. To measure oligomeric and insoluble Aβ3 from total brain homogenate, a 2-step serial extraction procedure was used as described previously with modification. In brief, the remained pellet following soluble Aβ3 extraction was mixed with 2% SDS in PBS containing protease arrest with homogenization, followed by sonication for 10 min and centrifugation at 20,817 x g for 60 min at 22 °C. The supernatant was collected and stored in −80 °C. To isolate insoluble Aβ3, the pellet from the second fractionation was re-suspended in 70% formic acid in PBS containing protease arrest, followed by homogenization and sonication for 10 min, and finally centrifugation at 20,817 x g for 60 min at 4 °C. In addition, to measure total Aβ42 and Aβ342, 70% formic acid was added to brain homogenate, followed by homogenization, sonication, and centrifugation as described above. Supernatant was collected and stored in −80 °C. The formic acid fraction was neutralized 1:20 with 1 M Tris/0.5 M Na2HPO4. The soluble, oligomeric and insoluble Aβ42 and Aβ342 were measured separately by two commercial ELISA kits (Thermo Fisher Scientific) for Aβ42 and Aβ342.

Fractionation of lipid rafts. Lipid rafts fractionation was performed as reported previously with modification. Eighty microliters from each brain homogenate in DPBS was mixed with 600 µl of 1% Brij® 98, 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM PMSE, and then incubated on ice for 30 min. The suspension was centrifuged at 1,000 x g for 5 min at 4 °C. Five hundred microliters from sample supernatant was mixed with equal volume of 80% (wt/vol) sucrose in TNE buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA) and placed at the bottom of an ultracentrifuge tube. Then, 4 ml discontinuous sucrose gradients in TNE buffer consisting of 3 ml 35% (wt/vol) sucrose and 1 ml 3% (wt/vol) sucrose were overlayered on the top. The sucrose gradient was centrifuged at 260,000 x g for 3 h at 4 °C using Beckman Coulter ultracentrifuge in SW55 Ti rotor. The fractions (500 µl) each from sample were collected from top to bottom of the tube and then stored in −80 °C until analysis.

Western blot analysis. Brain homogenates in DPBS were lysed on ice for 45 min with NP-40 lysis buffer containing protease arrest and then centrifuged at 20,817 x g for 15 min at 4 °C, followed by collecting and storing the supernatant for immunoblotting. Total protein content was measured by Pierce™ BCA Protein Assay kit (Thermo Fisher Scientific). Equal amounts of protein (20 µg) from brain homogenate lysates and lipid raft fractions were subjected to SDS-PAGE followed by immunoblot analysis according to a standard procedure. To detect proteins, 12% Tris-glycine polyacrylamide gels were used. For GM1 detection, 15% gels for GM1 separation
were used, membranes were then blocked and incubated with Cholera Toxin Subunit B (recombinant)-HRP for 1 h at room temperature with shaking followed by imaging. For amylin receptor (RAMP3) immunoblotting, we used commercially available stain free kit (Bio-Rad). Blots were developed using a chemiluminescence detection kit (SuperSignal West Femto substrate; Thermo Fisher Scientific); bands were visualized by ChemiDoc imaging system (Bio-Rad) and then analyzed by Image Lab software v6.0 (Bio-Rad). The results were expressed as fold change in protein level compared to control group after normalization to the house keeping proteins.

**Immunohistochemistry analysis.** Brain sections of 16 μm-thick were prepared using Leica CM3050S Research Cryostat. All brains slices were methanol-fixed and blocked for 30 min with 10% normal donkey serum in PBS. For the detection of Aβ-plaques load, we followed a previously published protocol with slight modification62. Briefly, the sections were immuno stained with rabbit polyclonal collagen IV antibody (1:200) to detect brain microvessels followed by donkey polyclonal Alexa Flour 647 antibody to rabbit IgG (1:200), which were then incubated in filtered 0.02% thioflavin-S (Thio-S) solution prepared in 70% ethanol for 30 min to detect Aβ deposits. Sections were then washed in 70% ethanol for 15 min and covered with cover-clips for imaging. For total Aβ load detection, brain slices were double immunostained for microvessels and Alexa Flour-488 conjugated anti-Aβ antibody (6E10) (1:200). Double immunostaining of astrocytes and Aβ3 was performed using rabbit GFAP antibody (1:200), and for detection donkey polyclonal Alexa Flour 647 antibody to rabbit IgG (1:200) was used. For each treatment, image acquisition was performed in 10 tissue sections spanning the hippocampus, each separated by 150 μm (total of 40 sections per mouse). Images were captured using Nikon Eclipse Ti –2 inverted fluorescence microscope (Nikon). Quantification of all images was performed using NISeelement AR analysis v5 (Nikon) after adjusting for threshold.

**GM2 ganglioside analysis by ELISA.** Brain homogenate in DPBS was diluted 1:5 with PBS and centrifuged at 950 x g for 20 min at 4°C. GM2 was measured in the supernatant following the manufacturer protocol (MyBioSource, Cat # MBS017456). GM2 was also measured in lipid rafts and the level of GM2 from total brain homogenate and lipid rafts were normalized to protein content in total brain homogenate.

**Assay of lysosomal enzyme activities.** The lysed brain homogenate in NP-40 lysis buffer was diluted 1:1 in citrate phosphate buffer and the lysosomal enzyme activities for beta-galactosidase (β-gal); hexosaminidase A (HexA), total hexosaminidase (A,B and S isozymes; Hex T), and alpha-mannosidase (α-Man) were measured with synthetic substrates based on released amount of 4-methylumbelliferone as previously described64. α-Man cleaves lysosomal substrates outside the the gangliosides pathway and it is used as assay control.

**Statistical analysis.** All values were expressed as mean ± SEM. Statistical analysis was done with Prism v5.0 software (Graphpad). The statistical significance for all result was assessed by Student t-test. A p value of <0.05 was considered statistically significant.

**Data availability**

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Received: 2 July 2019; Accepted: 4 February 2020;
Published online: 28 February 2020

**References**

1. Selkoe, D. J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. *Ann. N. Y. Acad. Sci.* 924, 487–498 (2010).
2. Harrington, C. R. The Molecular Pathology of Alzheimer's Disease. *Neuroimaging Clin. N. Am.* 22, 11–22 (2012).
3. Thinakaran, G. & Koo, E. H. Amyloid precursor protein trafficking, processing, and function. *J. Biol. Chem.* 283, 29615–29619 (2008).
4. De Strooper, B. & Annaert, W. Proteolytic processing and cell biological functions of the amyloid precursor protein. *J. Cell Sci.* 113, 1857–1870 (2000).
5. Zhan, Q. Homogenate and lipid rafts were normalized to protein content in total brain homogenate. (MyBioSource, Cat # MBS017456). GM2 was also measured in lipid rafts and the level of GM2 from total brain homogenate and lipid rafts were normalized to protein content in total brain homogenate.
6. Shibata, M. et al. Amyloidogenic processing of the Alzheimer type 2 diabetes mellitus and Alzheimer's disease. *World J. Diabetes* 5, 889–893 (2014).
7. Gasic-Milenkovic, J. et al. Synaptic changes in alzheimer's disease. Increased amyloid-β and gliosis in surviving terminals is accompanied by decreased psd-95 fluorescence. *Am. J. Pathol.* 165, 1809–1817 (2004).
8. Ehehalt, R., Keller, P., Haass, C., Thiele, C. & Simons, K. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. *J. Cell Biol.* 160, 113–123 (2003).
9. Gylys, K. H. et al. Type 2 diabetes mellitus and Alzheimer's disease. *Am. J. Pathol.* 165, 28110–28117 (2005).
10. Harrington, C. R. The Molecular Pathology of Alzheimer's Disease. *Neuroimaging Clin. N. Am.* 22, 11–22 (2012).
11. Hattori, C. et al. BACE1 interacts with lipid raft proteins. *J. Neurosci. Res.* 84, 912–917 (2006).
12. Vetrivel, K. S. Spatial segregation of γ-secretase and substrates in distinct membrane domains. *J. Biol. Chem.* 280, 25892–25900 (2005).
13. Helms, J. B. & Zarzolo, C. Lipids as targeting signals: Lipid rafts and intracellular trafficking. *Traffic* 5, 247–254 (2004).
14. Yanagisawa, K., Odaka, A., Suzuki, N. & Hira, Y. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. *Nat. Med.* 1, 1062–1066 (1995).
15. Vassar, R. The β-secretase, BACE: A prime drug target for Alzheimer's disease. *J. Mol. Neurosci.* 17, 157–170 (2001).
16. Tamboli, I. Y. et al. Inhibition of glycosphingolipid biosynthesis reduces secretion of the β-amyloid precursor protein and amyloid β-peptide. *J. Biol. Chem.* 280, 28110–28117 (2005).
17. Zha, Q. et al. GM1 ganglioside regulates the proteolysis of amyloid precursor protein. *Mol. Psychiatry* 9, 946–952 (2004).
18. Babagallo, M. et al. Type 2 diabetes mellitus and Alzheimer's disease. *World J. Diabetes* 5, 889–893 (2014).
19. Westmark, P., Andersson, A. & Westmark, G. T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev. 91, 795–826 (2011).
20. Wimalawansa, S. J. et al. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit. Rev. Neurobiol. 11, 167–239 (1997).
21. Cooper, G. J. S. et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. USA 84, 8628–8632 (1987).
22. Eisenberg, D. & Jucker, M. The amyloid state of proteins in human diseases. Cell 148, 1188–1203 (2012).
23. Jackson, K. et al. Amylin deposition in the brain: A second amyloid in Alzheimer disease? Ann. Neurol. 74, 517–526 (2013).
24. Trevaskis, J. L. et al. Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats. Endocrinol. 151, 3657–3668 (2010).
25. Lim, Y. A., Ittner, L. M., Lim, Y. L. & Götz, J. Human but not rat amylin shares neurotropic properties with A3/42 in long-term hippocampal and cortical cultures. FERS Lett. 582, 2188–2194 (2008).
26. Wu, W. et al. Amyloid (β) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J. Biol. Chem. 287, 18820–18830 (2012).
27. Liu, W. Q. et al. Insulin-degrading enzyme regulates extracellular levels of amyloid-β protein by degradation. J. Biol. Chem. 273, 32730–32738 (1998).
28. Oskarsson, M. E. et al. In vivo seeding and cross-seeding of localized amyloidosis: A molecular link between type 2 diabetes and Alzheimer disease. Am. J. Pathol. 185, 834–846 (2015).
29. Mohamed, L. A. et al. Amylin enhances amyloid-β peptide brain to blood efflux across the blood-brain barrier. J. Alzheimer’s Dis. 56, 1087–1099 (2017).
30. Wang, E. et al. Amylin treatment reduces neuroinflammation and ameliorates abnormal patterns of gene expression in the cerebral cortex of an Alzheimer’s disease mouse model. J. Alzheimer’s Dis. 56, 47–61 (2017).
31. Zhu, H. et al. Amylin receptor ligands reduce the pathological cascade of Alzheimer’s disease. Neuropharmacol. 119, 170–181 (2017).
32. Zhu, H. et al. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer’s disease. Mol. Psychiatry 20, 252–262 (2015).
33. Yamaguchi, T. et al. Expression of B4GALNT1, an essential glycosyltransferase for the synthesis of complex gangliosides, suppresses BACE1 degradation and modulates APP processing. Sci. Rep. 6, 34505 (2016).
34. Götz, J., Lim, Y. A. & Eckert, A. Lessons from two prevalent amyloidoses: What amylin and A3/4 have in common. Front. Aging Neurosci. 5, 38–47 (2013).
35. Baranello, R. J. et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer’s disease. Curr. Alzheimer Res. 12, 32–46 (2015).
36. Qin, W. Q. & Folstein, M. F. Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer’s disease: Review and hypothesis. Neurobiol. Aging 27, 190–198 (2006).
37. Grossi, C. et al. The polyphenol oleuropein aglycone protects TgCRND8 mice against Aβ plaque pathology. PLoS One 8, e71702 (2013).
38. Banks, W. A. & Kastin, A. J. Differential permeability of the blood–brain barrier to two pancreatic peptides: Insulin and amylin. Peptides 19, 883–889 (1998).
39. Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G. & Roth, J. D. Amylin: pharmacology, physiology, and clinical potential. Pharmacol. Rev. 67, 564–600 (2015).
40. Qin, W. Q. Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer’s disease. Neurosci. 356, 44–51 (2017).
41. Adler, B. L. et al. Neuroprotective and neuroregenerative properties of the amylin analogue pramlintide on Alzheimer’s disease pathogenesis and cognition. Neurobiol. Aging 35, 793–801 (2014).
42. Fu, W., Patel, A. & Jhamandas, J. H. Amylin receptor: A common pathophysiological target in Alzheimer’s disease and diabetes mellitus. Front. Aging Neurosci. 5, 42–45 (2013).
43. Jhamandas, J. H. Antagonist of the amylin receptor blocks -amyloid toxicity in rat cholinergic basal forebrain neurons. J. Neurosci. 24, 5579–5584 (2004).
44. Verma, N. et al. Intraneuronal amylin deposition, peroxiormative membrane injury and increased il-1β synthesis in brains of Alzheimer’s disease patients with type-2 diabetes and in diabetic hip rats. J. Alzheimer’s Dis. 53, 259–272 (2016).
45. Soudy, R. et al. Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer’s disease. Alzheimers Dement. Transl. Res. Clin. Interv. 3, 44–56 (2016).
46. Kimura, R., MacIntosh, D., Yang, J., Westaway, D. & Jhamandas, J. H. Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor. J. Neurosci. 32, 17401–17406 (2012).
47. Davis, J. et al. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 279, 20269–20306 (2004).
48. Hong, S. et al. Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuroat. 82, 308–319 (2014).
49. Yamagisaka, K. Role of gangliosides in Alzheimer’s disease. Biochim. Biophys. Acta 1768, 1943–1951 (2007).
50. Gellermann, G. P. et al. Raft lipids as common components of human extracellular amyloid fibrils. Proc. Natl. Acad. Sci. USA 102, 6297–6302 (2005).
51. Wakabayashi, M. & Matsuzaki, K. Ganglioside-induced amyloid formation by human islet amyloid polypeptide in lipid rafts. FERS Lett. 583, 2854–2858 (2009).
52. Engel, M. F. Membrane permeabilization by Iset Amyloid Polypeptide. Chem. Phys. Lipids 160, 1–10 (2009).
53. Ikeda, K., Yamaguchi, T., Fukunaga, S., Hoshino, M. & Matsuzaki, K. Mechanism of amyloid-β protein aggregation mediated by GM1 ganglioside clusters. Biochem. 50, 6433–6440 (2011).
54. Matsuzaki, K. Formation of toxic amyloid fibrils by amyloid-β protein on ganglioside clusters. Int. J. Alzheimers. Dis. 2011, 956104 (2011).
55. Wu, L. & Gonias, S. L. The low-density lipoprotein receptor-related protein-1 associates transiently with lipid rafts. J. Cell. Biochem. 96, 1021–1033 (2005).
56. Laudati, E. et al. The activities of LDL Receptor-related Protein-1 (LRP1) compartmentalize into distinct plasma membrane microdomains. Mol. Cell. Neurosci. 76, 42–51 (2016).
57. May, P. et al. Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol. Cell. Biol. 24, 8872–8883 (2004).
58. Yoshii, A. & Constantine-Paton, M. BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation. Nat. Neurosci. 10, 702–711 (2007).
59. May, P. C., Boggs, L. N. & Fuson, K. S. Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer’s disease amyloid-β neurotoxicity. J. Neurochem. 61, 2330–2333 (1993).
60. Qin, W. Q. & Zhu, H. Amylin and its analog: A friend or foe for the treatment of Alzheimer’s disease? Front. Aging Neurosci. 6, 186–194 (2014).
61. Wang, C. et al. The role of posttraumatic hypothermia in preventing dendrite degeneration and spine loss after severe traumatic brain injury. Sci. Rep. 6, 37063 (2016).
62. Qosa, H. et al. Extra-virgin olive oil attenuates amyloid-β and tau pathologies in the brains of TgSwDI mice. J. Nutr. Biochem. 26, 1479–1490 (2015).
63. Wang, Z. & Schey, K. L. Proteomic analysis of lipid raft-like detergent-resistant membranes of lens fiber cells. Investig. Ophthalmo. Vis. Sci. 56, 8349–8360 (2015).
64. Martin, D. R. et al. Mutation of the GM2 activator protein in a feline model of GM2 gangliosidosis. Acta Neuropathol. 110, 443–450 (2005).

Acknowledgements
This research work was funded by the National Institute of Neurological Disorders and Stroke (NIH/NINDS) under grant number R15NS091934 (A.K.).

Author contributions
Y.M.M. performed experiments, analyzed the data and wrote the manuscript. M.H. performed the lysosomal enzymes activity assay. I.M.A. performed experiments and analyzed the data. D.R.M. managed lysosomal enzymes activity experimental process and edited the manuscript; A.K. was the principal director and study supervisor, responsible for the design of the study and securing fund.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-60664-5.

Correspondence and requests for materials should be addressed to A.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020